Thiadiazole irak4 inhibitors

Abstract

A compound of Formula (I), pharmaceutically acceptable salts thereof, deuterated analogs thereof, compositions thereof, and methods of treating disease by using a compound thereof are disclosed.

Description

technical field [0001] The present disclosure relates to novel compounds that are inhibitors of the kinase IRAK4. The present disclosure also relates to methods of preparing compounds and pharmaceutical compositions comprising such compounds. Background technique [0002] Interleukin-1 receptor-associated kinase-4 (IRAK4) is a serine-threonine kinase that acts as a mediator in the interleukin-1 / Toll-like receptor (IL-1 / TLR) signaling cascade. More specifically, IRAK4 is involved in the activation of the adapter protein myeloid differentiation primary response gene 88 (MyD88) signaling cascade and is hypothesized to play a role in inflammatory and fibrotic diseases such as rheumatoid arthritis (RA), inflammatory bowel disease (IBD). ), gout, Lyme disease, arthritis, psoriasis, pelvic inflammatory disease, systemic lupus erythematosus (SLE), Sjogren syndrome, viral myocarditis, acute and chronic tissue damage, nonalcoholic steatohepatitis ( NASH), alcoholic hepatitis and kid...

AI Technical Summary

Problems solved by technology

[0006] There are currently no approved IRAK4 inhibitors

Images